Skip to main content
Premium Trial:

Request an Annual Quote

Fisher Scientific to Distribute Response Bio's Ramp Cardiac Product in Canada

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fisher Scientific will exclusively distribute Response Biomedical's RAMP cardiac products in Canada under a deal announced today.

Financial and other terms of the agreement were not disclosed.

Fisher Scientific is part of Thermo Fisher Scientific.

According to Vancouver, British Columbia-based Response Biomedical, point-of-care testing in Canada is projected to reach C$63 million ($66.2 million) this year with an estimated growth rate of 7 percent over the next few years.

Response Bio's RAMP system consists of a reader and single-use disposable test cartridges. RAMP clinical tests are commercially available for the early detection of heart attack and congestive heart failure.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.